Navigation Links
New target for anti-flu drug development
Date:8/15/2007

Boston, August 15, 2007---Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.

Their findings have been published in the August 15, 2007 issue of the journal Cell Cycle.

The potential drug target is the flu protein M2, long known to be highly conserved between avian and human strains of the virus. Scientists at Cure Lab found that this M2 protein may single-handedly kill human cells.

This effect may constitute a previously unknown mechanism of influenza virus pathogenicity said Dr. Alex Shneider, senior author on the paper and CEO of the company. If so, drugs that are shown to prevent M2-dependent cell killing have the potential to be used for the treatment of flu.

Membranes covering human and avian cells do not allow ions to move in and out of the cell freely, thus maintaining internal homeostasis. M2 protein of flu virus forms ion channels allowing ion trafficking into cells that cells no longer control. Dr. Shneider and his group not only demonstrated that M2 kills mammalian cells, but also showed that ion channeling through M2 pores may be a molecular mechanism of this cell killing process. Dr. Shneider said that Developing drugs which block M2 ion channels could reduce or eliminate M2-induced cell death, and thus may be a new strategy for targeted development of anti-influenza drugs.

In collaboration with Dr. Vladimir L. Gabai from Boston University, and Dr. Shamil R. Sunyaev from Harvard Medical School scientist from Cure Lab, Inc. have developed mutant forms of M2 protein, where the ion channel is blocked. The researchers have shown that these specific mutations they introduced in the protein significantly reduc
'/>"/>

Contact: Alex Shneider
thoidis@curelab.com
609-841-1201
Cure Lab, Inc.
Source:Eurekalert

Page: 1 2

Related biology news :

1. New binding target for oncogenic viral protein
2. Ancient olfaction protein is shared by many bugs, offering new pest control target
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. A bacterial genome reveals new targets to combat infectious disease
5. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
6. Researchers identify target for cancer drugs
7. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
8. Potential Drug Target For Treating Cocaine Abuse Found
9. Study reveals candidate targets for anti-retroviral therapeutics
10. MUHC researchers make cancer target breakthrough
11. Future diabetes drugs may target new protein interaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 24, 2014)The link between autism and disrupted brain ... of the disease, and is largely unknown. However, ... Research Initiative (SFARI), George Washington University (GW) researcher ... truly integrative and in-depth answers to these key ... , LaMantia, professor of pharmacology and physiology at ...
(Date:7/25/2014)... Birla, associate professor of biomedical engineering at the ... on tissue engineering and artificial organ development., "Introduction ... comprehensive guide to entering into the field of ... professor of biomedical engineering at UH, served as ... that while there are other published books on ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2University of Houston researcher publishes textbook on tissue engineering 2
... Capabilities for Use in a Wide,Range ... Vision Applications, VILNIUS, Lithuania, Sept. ... provider of high-precision biometric,and object identification ... 2.0 SDK universal object recognition technology ...
... always good to respond maximally when pathogens or disease ... balance immediate and future costs? This is the question ... Tony Williams asked when they examined how a simple ... life-span of individual zebra finches ( Taeniopygia guttata ), ...
... of stripy legs in a camera trap photo snapped in ... from the Wildlife Conservation Society. The legs belong to an ... Republic of Congo,s Virunga National Park, despite over a decade ... the first time this species has been captured on film ...
Cached Biology News:Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 2Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 3Individuals vary their immune response according to age, sex and the costs 2Photo reveals rare okapi survived poaching onslaught 2
(Date:7/25/2014)... Calif. , July 25, 2014 Amgen ... of Directors today declared a $0.61 per share dividend ... be paid on Sept. 5, 2014, to all stockholders ... Aug. 14, 2014.  About Amgen Amgen ... patients suffering from serious illnesses by discovering, developing, manufacturing ...
(Date:7/25/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... at USD 161,056.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... is witnessing a significant growth due to the increasing ...
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... May 11 /PRNewswire-Asia-FirstCall/ -- China,Baicaotang Medicine Ltd. (OTC Bulletin Board: ... in the, Guangxi Province of China announced today that ... the,Company. , , , ... Mr. Tang Hui Tian , Chairman and CEO of CBT, ...
... of more affordable drugs, vaccines and diagnostics that would ... from a growing number of collaborations between biotech firms ... published Mon. May 10 in the UK journal ... countries, together with colleagues at Canada,s McLaughlin-Rotman Centre for ...
... May 10 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... pharmaceutical company producing over-the-counter drugs in, the People,s Republic of China , ... of $10.1 million for the first quarter,ended March 31, ... ...
Cached Biology Technology:Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 2Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 3Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 2Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 3Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 4Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 5Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 6Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 7China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 2China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 3China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 4China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 5China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 6
... Imaging System, Professional Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
... Corning single use spatulas have been ... samples. They are for those interested in ... reusable spatulas. Each spatula is individually packaged, ... CLS number is a new product number, ...
... digital valve, just 8 mm in width. ... in a single glass-reinforced, PBT (Polybutylene Terephthalate) molded ... width. , Meets a range of pressure requirements ... Satisfies a 0.016 sccm leakage specification (0.2 sccm ...
... FilterMate is a compact, versatile system that ... 96- or 24-well microplates into a solid ... liquid scintillation and gamma counter. The FilterMate ... for applications such as cell proliferation, receptor ...
Biology Products: